NEW YORK (GenomeWeb News) – GenOway, a French firm that develops transgenic mice and rats, began trading on Euronext’s Alternext exchange on April 5, the company said this week.
The company raised €27.7 million ($37.4 million) in its initial public offering, trading 5.6 million shares at €4.96 per share.
The company’s shares are trading at €6 today.
The Alternext, which opened two years ago, is a Euronext market designed for small and mid-cap companies.
GenOway develops genetically modified rat and mouse models for use in in vivo target validation and drug development.